103 results about "Mucoproteins" patented technology

The present invention provides an isolated Akkermansia muciniphila strain, composition comprising the same, and use thereof, which can be used for treating, preventing, or alleviating obesity, metabolic disorders induced by obesity, diabetes, inflammation, liver and kidney diseases, liver diseases, cardiovascular and cerebrovascular diseases, brain aging, tumors, etc. Additionally, it can be used for preventing and treating metabolic disorders after discontinuation of GLP-1 receptor agonist drugs, preventing weight rebound and blood glucose rebound, and maintaining glucose homeostasis.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

The present invention relates to Akkermansia muciniphila Akk11 having the functions of regulating blood glucose and blood fat and the use thereof. Said Akkermansia muciniphila Akk11 is classified and named as Akkermansia muciniphila Akk11 with the accession number of CCTCC NO: M2024119. The strain uses mucin as the unique source of carbon element and nitrogen element, so as to control the basic regulatory systems of glucose and energy metabolism, protect the integrity of intestinal epithelial cells and mucus layers to exert a protective effect on metabolism, regulate the levels of blood glucose and blood fat, and remarkably relieve symptoms of metabolic disorders, and thus providing strategies and reference basis for the prevention and treatment of obesity.

The application provides a mussel mucin synthesis method and relates to the technical field of genetic engineering.The application improves the yield of mussel mucin by carrying out deletion mutation on the N-terminal sequence of the secondary structure of the mussel mucin amino acid sequence such as SEQ ID NO.1.The yield of mussel mucin in the prior art is about 2.57g / L, while the yield of mussel mucin in the application is about 5g / L, which is greatly improved compared with the yield of mussel mucin in the prior art.On this basis, the mussel mucin is modified by dopa through co-expression of tyrosinase, and the expression amount of the tyrosinase is controlled through different intensities of RBS, so as to regulate the modification degree of dopa, improve the yield of mussel mucin, and realize controllable modification of dopa in the mussel mucin, finally obtaining mussel mucin with high yield and different modification degrees of dopa.

The application discloses a plant lactobacillus strain and application thereof, and belongs to the technical field of microorganisms. The preservation number of the strain is CGMCC No. 33864. The strain has good tolerance to gastrointestinal juice and bile salts and has no hemolytic activity. Concentrated cell-free supernatant prepared from the strain can inhibit salmonella, including inhibiting the growth of salmonella, killing bacteria, inhibiting or removing biofilm. Animal experiments show that the strain and the concentrated cell-free supernatant thereof can prevent salmonella infection, alleviate weight loss caused by infection, maintain intestinal barrier integrity, reduce the level of pro-inflammatory factors, alleviate tissue damage, improve the expression of colon tight junction proteins and mucin, promote the generation of short-chain fatty acids, and restore the intestinal flora structure. The application further provides a microbial preparation containing the strain and / or the concentrated cell-free supernatant thereof. The strain and the microbial preparation can be used for preparing products for resisting salmonella, preventing salmonella infection or improving intestinal health.

The invention relates to a chemoenzymatic synthesis method of a high-glucose-type homogeneity mucoprotein core structural domain. The method comprises the following steps: firstly, catalytically synthesizing a key alpha-linked glycosylated amino acid block Fmoc-GalNacalpha-Ser / Thr-OH at a low temperature (-20 DEG C to 0 DEG C); then assembling the building blocks on a repeated polypeptide skeleton rich in proline, serine and threonine at accurate intervals (3-5 amino acid residues) through a solid-phase peptide synthesis technology to form a'sugar chain growth scaffold '; then, a series of high-specificity glycosyl transferases are used for carrying out sequential and directional sugar chain enzymatic extension on the scaffold, and a uniform core structure (such as a core type 3) is constructed; and finally, performing high-efficiency purification by a three-step series method of size exclusion chromatography, ion exchange chromatography and lectin affinity chromatography. The technical bottleneck of inhomogeneity (lt, 70%) of glycoforms in a traditional method is overcome, the mucoprotein core fragment with glycoform homogeneity larger than or equal to 95% and bioactivity highly similar to that of natural mucoprotein can be prepared on a large scale, and the method has wide application prospects in the biomedical fields of mucous membrane protective agents, drug delivery carriers and the like.

The invention relates to the technical field of medical biological materials, and discloses a mussel mucin-chondroitin sulfate composite hydrogel and a preparation method and application thereof, and the preparation method comprises the following steps: respectively preparing a mussel mucin aqueous solution and a chondroitin sulfate aqueous solution; the mass volume concentration of the mussel mucoprotein aqueous solution is 1%-10%, the mass volume concentration of the chondroitin sulfate aqueous solution is 1%-10%, the mass ratio of the mussel mucoprotein to the chondroitin sulfate is 3: 1-1: 3, the two solutions are mixed and stirred or oscillated under the conditions that the temperature is 4-37 DEG C and the pH value is 7.0-9.0, a cross-linking reaction is conducted, and hydrogel is formed; the cross-linking mode is physical cross-linking, chemical cross-linking or physical-chemical dual cross-linking; according to the invention, excellent tissue adhesion, injectability, self-healing property and biodegradability are realized, cell adhesion and proliferation can be effectively promoted, and the gel is suitable for various medical beauty scenes such as skin filling, wound repairing and anti-aging nursing.

The invention discloses a preparation method of Chinese yam mucin anti-drag hydrogel. The preparation method comprises the following steps: crushing Chinese yam blocks and deionized water to obtain a Chinese yam mucus mixture; centrifuging, standing and layering, extracting supernate, and filtering to obtain a plant extracting solution; purifying by adopting a reverse osmosis method, and air-drying to obtain Chinese yam mucoprotein; the preparation method comprises the following steps: adding gelatin into a PBS solution, heating and stirring, then adding N, N-dimethylformamide and methacrylic anhydride, heating and stirring, dialyzing, and freeze-drying to obtain a gelatin derivative grafted with carbon-carbon double bonds; the preparation method comprises the following steps: adding a gelatin derivative into deionized water, heating and stirring, adding Chinese yam mucoprotein, N, N '-methylene bisacrylamide and ammonium persulfate, stirring, centrifugally defoaming, and drying to obtain the Chinese yam mucoprotein drag-reducing hydrogel. According to the preparation method of the Chinese yam mucoprotein anti-drag hydrogel, Chinese yam mucoprotein macromolecular chains are connected into a network structure by using N, N '-methylene bisacrylamide molecules, so that water-soluble Chinese yam mucoprotein is prevented from being dissolved and lost in a water body, and long-term lubrication and anti-drag are realized.

The invention provides a biological sustained-release stent as well as a preparation method and application thereof, and belongs to the technical field of biological materials. The biological sustained-release stent is prepared from the following raw materials in parts by weight: 35 parts of alkoxy-terminated polydimethylsiloxane, 15 parts of cyclopentanosiloxane, 5 parts of recombinant mussel mucin, 0.3 part of trifluoroacetic acid, 3 parts of trehalose and 2 parts of thioether-containing PTU polymer. The nucleotide sequence of the gene for coding the recombinant mussel mucin is as shown in SEQ ID NO. 1. According to the invention, the biological response type sustained-release stent is constructed through dynamic crosslinking of a mussel adhesive protein DOPA group and silicone molecules, and a wound microenvironment (pH / ROS) self-adaptive release function can be realized. The biological sustained-release scaffold is high in tensile strength and high in active ingredient retention rate, and various functional active ingredients in the biological scaffold have a synergistic effect.

The invention is applicable to the technical field of biopharmacy process, and provides a freeze-drying method for improving the bioactivity of recombinant mussel mucin, which comprises the steps of pretreatment, pre-freezing, primary drying and secondary drying. In the pretreatment step, a recombinant mussel mucoprotein solution with the pH value of 3.5-5.5 is mixed with a composite protective agent composed of trehalose, L-arginine and poloxamer according to a specific proportion; in the pre-freezing process, slow-fast-slow sectional cooling is adopted; drying adopts a vacuum drying mode combining gradient heating and gradient vacuum degree; according to the invention, creative coupling of the protective agent and the process is realized, the retention rate of the prepared product DOPA is more than 90%, the residual moisture is lower than 1.5%, the redissolution time is shorter than 30 seconds, the microstructure is excellent, and the long-term storage stability is good.

The present invention relates to a linker unit-cytotoxic small molecule drug, an antibody specifically binding to target mucoprotein 17 (MUC17), an antibody drug conjugate and uses thereof, and a composition and a detection system containing the antibody molecule, the linker unit-cytotoxic small molecule drug and the antibody drug conjugate.

The invention belongs to the technical field of gel preparation, and particularly relates to mussel mucoprotein physical barrier protective gel and a preparation method thereof. The mussel mucin polymer disclosed by the invention can quickly form a compact and flexible isolating membrane with self-repairing capability on the surface of vaginal mucosa. The isolating membrane can be firmly attached to the surface of a mucous membrane based on the strong biological adhesiveness of mussel mucin, can directly block sperm penetration and limit sperm swimming, and also can effectively block pathogenic microorganisms such as viruses and bacteria from contacting the mucous membrane. The acid environment provided by the lactic acid-citric acid buffer system not only can directly inhibit sperm activity, but also can enhance the stability and adhesiveness of the mussel mucin polymer, so that the mussel mucin polymer can be better attached to vaginal mucosa, and the action time of a physical barrier is prolonged. The chitosan quaternary ammonium salt has the effects of killing bacteria and viruses and the like, and the hydroxypropyl methyl cellulose serving as a thickening agent can improve the viscosity and the stability of the gel, so that the gel can be better retained in the vagina, and the action time is prolonged.

To provide epithelial cadherin-specific antibodies, and their use in the diagnosis and treatment of diseases such as cancer. [Solution] The above problem is solved by an antibody or antigen-binding fragment that specifically binds one or more O-mannosylated threonine residues of E-cadherin, wherein the one or more O-mannosylated threonine residues are located within amino acid positions 467 to 472 of the E-cadherin sequence.

This disclosure provides methods for treating endometrial cancer, reducing its severity, or inhibiting its growth. The methods of this disclosure comprise administering to a subject in need a single therapeutically effective amount of a bispecific antibody that specifically binds to mucin 16 (MUC16) and CD3, or administering said bispecific antibody in combination with a therapeutically effective amount of an antibody specifically binding to the programmed death 1 (PD-1) receptor or an antigen-binding fragment thereof.

The invention relates to the technical field of biological materials, in particular to chitosan-mussel mucin bionic polypeptide-SVF composite hydrogel as well as a preparation method and application thereof. The mussel mucin bionic polypeptide endows the hydrogel with strong adhesion capacity, so that the hydrogel can be firmly adhered to the surface of cartilage, and SVF loss is prevented; as a carrier of the SVF, the hydrogel can be fixed in an articular cavity, the retention time of the hydrogel is prolonged, and the treatment effect is continuously achieved. Chitosan and mussel mucin bionic polypeptide have good biocompatibility and do not cause immunological rejection, an RGD sequence in the polypeptide can promote cell adhesion, chitosan provides a good cell growth microenvironment, and colonization, survival and function exertion of cells in SVF are facilitated. Chitosan has a certain cartilage repair promoting effect and has a synergistic effect with SVF, cartilage regeneration can be more effectively promoted, a hydrogel precursor solution has good fluidity, the hydrogel precursor solution can be injected into an articular cavity in a minimally invasive mode, and operation is easy and convenient.

The present application relates to a kind of probiotic oil agent for improving non-alcoholic fatty liver disease, preparation method and application, the probiotic oil agent includes active ingredient A and active ingredient B, the active ingredient A is mucinophilic Akkermansia Akk11, and the preservation number is CCTCC NO:M2024119;The active ingredient B is Omega-3 fatty acid.The present application is combined with mucinophilic Akkermansia Akk11 and Omega-3 fatty acid, and is prepared into oil agent, and the improvement of NAFLD symptom can play the coordinated synergistic effect, can be used for the prevention and treatment of NAFLD.

The present invention relates to binding antibodies targeting Mucin 17 (MUC17). The present invention further relates to detection systems comprising such antibodies for the diagnosis of diseases and / or disorders associated with aberrant expression of MUC17.

The invention belongs to the technical field of food functional ingredients and biological materials, and particularly discloses an oral cavity lubrication composition, an additive and a preparation method and application of the oral cavity lubrication composition and the additive. The lubrication enhancer is one or more of sugar alcohol compounds; the interface stabilizer is one or more of mammal-derived mucoproteins. According to the oral cavity lubricating composition, the additive and the preparation method and application of the additive, the preparation process is simple and controllable, the lubricating additive has good biocompatibility, the lubricating effect in the oral cavity is remarkably improved, the oral cavity dryness is relieved, the food oral cavity digestion effect is improved, and the additive is suitable for improving oral cavity dysfunctions such as the xerostomia.

The invention discloses a fermentation process for improving the yield of recombinant mussel mucin. According to the fermentation process, the utilization efficiency of a nitrogen source is enhanced by optimizing microbial metabolism distribution, and the catalytic activity of a key enzyme is improved; cell damage caused by environmental stress is relieved by means of a cell membrane protection mechanism, and the apoptosis rate is reduced; finally, the stability of cells in the fermentation process is remarkably enhanced, the fermentation expression quantity of the recombinant mussel mucin is greatly improved, and the industrial production level of target protein is comprehensively improved.

Disclosed herein are double stranded ribonucleic acids (dsRNAs) and synthetic antisense oligonucleotides (ASOs) for use in inhibiting the expression of MUC5B and in the treatment of a subject having a disease or disorder characterized by overexpression of MUC5B, including in subjects having lung disease or in a subject at risk of developing lung disease, for example, in a subject having or at risk of developing idiopathic pulmonary fibrosis.

1. Name of the designed product: packing box (mussel adhesive protein anorectal dressing). 2. Use of the designed product: for packing products. 3. Design points of the designed product: in the combination of shape and pattern. 4. Picture or photo best indicating the design points: front view.

The invention relates to the technical field of egg white protein extraction, and discloses stem cell egg powder derived from fertilized eggs and a preparation method and application of the stem cell egg powder. According to the method, a specific low-temperature graded salting-out path is constructed, impurities such as ovomucin are selectively removed through the first-stage sodium sulfate precipitation, the purity of the extract is improved, the purity of the extract is improved, and the purity of the extract is improved. And a clean solution background is created for the second-stage sodium chloride precipitation, so that the unification of high-activity retention and high-purity separation of the target active protein is realized under low-temperature operation in the whole process.

The invention belongs to the technical field of biomedical materials, and particularly relates to an antioxidant for improving the stability of mussel mucin and application of the antioxidant. The antioxidant provided by the invention is a combination of an antioxidant A and an antioxidant B, or a combination of the antioxidant A, the antioxidant B and an antioxidant C. The antioxidant A is composed of Ectoine, mussel mucin type 6 (Mfp-6), glycerin and polyvinylpyrrolidone (PVP), the antioxidant B is an antioxidant containing reduced sulfur, and the antioxidant C is a hydrogen supply type antioxidant. The mussel mucin is protected by the components in the antioxidant through multiple mechanisms, so that the oxidation degree and the oxidation rate of the mussel mucin in the mussel mucin preparation are obviously slowed down.

The present invention relates to a bifunctional peptide comprising a virus-binding portion (2) and a mucin-binding portion (1) covalently linked to the virus-binding portion (2). The virus-binding portion is selected from peptides that bind to SARS-CoV-2, influenza A virus, influenza B virus, rhinovirus and other enteroviruses, human parainfluenza virus, and / or metapneuvirus. The mucin-binding portion is selected from lectins such as trefoil factor 3.

The present application relates to a serine protease that selectively degrades mucin and uses thereof. The serine protease is serine protease EatA, and the protein contains a passenger domain with serine protease EatA activity, and the amino acid sequence of the passenger domain is at least 90% identical to SEQ ID NO: 2, preferably the amino acid sequence shown in SEQ ID NO: 2. The serine protease EatA can selectively degrade mucin in disease-related mucus and is highly stable over a long period of time.

This invention relates to the field of microcapsule preparation technology, and more particularly to a method for preparing probiotic microcapsules. The invention involves mixing a probiotic suspension with a tris(2-carboxyethyl)phosphine solution and performing a reduction reaction to obtain a thiolized probiotic suspension. Then, a thiolized polysaccharide is mixed with the thiolized probiotic suspension and subjected to a covalent bonding reaction to obtain probiotic microcapsules. This invention uses a simple chemical reaction to reduce the disulfide bonds on the surface of probiotics to free thiols, enabling the thiolized polysaccharide and probiotics to covalently bind, resulting in a stronger bond between the polysaccharide and the probiotics. The microcapsules prepared from the modified polysaccharide and probiotics can also bind to the mucin-rich mucus layer in the intestinal lining, undergoing a catalyst-free thiol-disulfide exchange reaction, colonizing the mucus layer in the intestine, and producing better therapeutic effects for intestinal diseases and enhanced probiotic benefits.

The invention relates to a recombinant mussel mucin MFP535. The invention further provides a coding nucleic acid, a recombinant vector, a recombinant strain and the like for highly expressing the MFP535, so that the efficient expression of the recombinant mussel mucin MFP535 is realized. The invention further provides a purification and separation method for the recombinant mussel mucin MFP535, the purity of the MFP535 finally obtained through purification reaches 96% or above, the tyrosine oxidation rate reaches 0.44%, and the endotoxin is lt; 1 EU / mg. The recombinant mussel mucin MFP535 has an obvious effect of promoting cell growth. The separation and purification method disclosed by the invention is high in specificity, mild in operation condition, simple in step, good in purification effect, high in recovery rate, low in cost, high in speed and beneficial to expanded production.

The invention provides three Cry1Ac modified toxin proteins with high insecticidal activity and application of the Cry1Ac modified toxin proteins, and relates to the field of genetic engineering and biological control. The amino acid sequences of the three modified proteins are sequentially shown as SEQ ID NO: 1, SEQ ID NO: 3 and SEQ ID NO: 5, and the amino acid sequences are sequentially shown as SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 6. The insect-resistant protein is a Cry1Ac toxin modified protein with improved insecticidal activity, which is screened from a Cry1Ac toxin key region saturation mutation library targeting Asiatic corn borer cadherin and ABC transporter, has higher insecticidal activity on lepidoptera pests, can be used for preventing and controlling agricultural pests and resisting the Bt resistance problem, and has important scientific and practical significance.

Provided herein are anti-T Cell Immunoglobulin and Mucin Protein-3 (TIM-3) antibodies having particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences and methods of using the anti-TIM-3 antibodies to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.